Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 9/20 | 0.45 |
| ▸ | EGFR | P00533 | 8/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256370 | 0.75 | MKNK2 (0.45) | MKNK2EGFRMKNK1CYP1A2CYP3A4 | |
| SCHEMBL2319181 | 0.75 | MKNK2 (0.45) | MKNK2EGFRMKNK1PRMT5WDR77 | |
| SCHEMBL30694603 | 0.75 | MKNK2 (0.45) | MKNK2EGFRMKNK1CYP1A2CYP3A4 | |
| SCHEMBL27821267 | 0.75 | MKNK2 (0.45) | MKNK2EGFRMKNK1CYP1A2CYP3A4 | |
| SCHEMBL22622580 | 0.75 | MKNK2 (0.45) | MKNK2EGFRMKNK1CYP1A2CYP3A4 | |
| SCHEMBL18938889 | 0.75 | MKNK2 (0.45) | MKNK2EGFRMKNK1CYP1A2CYP3A4 | |
| SCHEMBL24823940 | 0.71 | MKNK2 (0.42) | MKNK2EGFRMKNK1PRMT5WDR77 | |
| SCHEMBL5021603 | 0.71 | MKNK2 (0.42) | MKNK2EGFRMKNK1CYP1A2CYP3A4 | |
| SCHEMBL5068124 | 0.71 | MKNK2 (0.42) | MKNK2EGFRMKNK1PRMT5WDR77 | |
| SCHEMBL6364432 | 0.71 | MKNK2 (0.42) | MKNK2EGFRMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822339-B2 | Pyrrolopyrimidine five-membered azacyclic derivative and application thereof | HANGZHOU HUADONG MEDICINE GROUP BIOPHARMACEUTICAL CO. LTD (CN) | 2020-11-03 | — | — | US | disclosed |
| US-20190040068-A1 | PYRROLOPYRIMIDINE FIVE-MEMBERED AZACYCLIC DERIVATIVE AND APPLICATION THEREOF | Hangzhou Bangshun Pharmaceutical Co., Ltd. (CN) | 2019-02-07 | — | — | US | disclosed |
| WO-2009143018-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040068-A1 | PYRROLOPYRIMIDINE FIVE-MEMBERED AZACYCLIC DERIVATIVE AND APPLICATION THEREOF | JAK2, JAK1, JAK3 | MKNK2 386/4885EGFR 2218/4885MKNK1 348/4885 |
| US-10822339-B2 | Pyrrolopyrimidine five-membered azacyclic derivative and application thereof | JAK2, JAK1, JAK3 | MKNK2 621/4885EGFR 1777/4885MKNK1 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.